Adjuvant hormone therapy for improvement of disease control in patients with non-metastatic prostate cancer with poor prognosis

N. Fleshner
Princess Margaret Hospital, Toronto, Ontario
Canada

Division of Urology

T. E. Keane
Medical University of South Carolina, Charleston, SC
United States

C. A. Lawton
Medical College of Wisconsin, Milwaukee, WI
United States

P. F. Mulders
University Hospital Nijmegen, Nijmegen
Netherlands

H. Payne
Meyerstein Institute of Oncology, Middlesex Hospital, London
United Kingdom

S. S. Taneja
New York University School of Medicine, New York, NY
United States

T. Morris
AstraZeneca, Alderley Park, Macclesfield
United Kingdom